HEMATOLOGIC
MALIGNANCIES

The Hematologic Malignancies (HEM) research program focuses on advancing our understanding of molecular pathogenesis and treatment of leukemias and lymphomas.

About the Program

MEMBERSHIP RESOURCES

BECOME A MEMBER

EVENTS

VIEW EVENTS

Recent Publications by HEM Members

October 2025

The proteostasis network is a therapeutic target in acute myeloid leukemia

October 2025

Proteostasis disruption in inherited bone marrow failure syndromes

July 2025

RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCT

Inside the Lab: Researcher Spotlight with HEM Member Shiri Gur-Cohen, PhD

Watch Now

News & Discoveries

Stem Cells, Space, and the Future of Regenerative Medicine

Christopher K. Glass, MD, PhD Appointed Director of UC San Diego Center for Epigenomics (C4E)

HEMATOLOGIC MALIGNANCIES

MEMBERSHIP RESOURCES

EVENTS

Recent Publications by HEM Members

The proteostasis network is a therapeutic target in acute myeloid leukemia

Proteostasis disruption in inherited bone marrow failure syndromes

RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCT

Inside the Lab: Researcher Spotlight with HEM Member Shiri Gur-Cohen, PhD

News & Discoveries

Stem Cells, Space, and the Future of Regenerative Medicine

Christopher K. Glass, MD, PhD Appointed Director of UC San Diego Center for Epigenomics (C4E)

AI Model Powers Skin Cancer Detection Across Diverse Populations

HEMATOLOGIC
MALIGNANCIES